Table:
|  | 31 March 2019 | 31 March 2018 Restated See note 2 |
| --- | --- | --- |
|  | $M | $M |
| Current |  |  |
| Trade receivables | 128.7 | 151.8 |
| Prepayments | 26.9 | 23.1 |
| Deferral of contract acquisition costs | 31.5 | 29.5 |
| Other receivables | 8.2 | 6.4 |
| Total current trade and other receivables | 195.3 | 210.8 |
| Non-current |  |  |
| Deferral of contract acquisition costs | 15.1 | 16.2 |
| Other receivables | 1.3 | 1.3 |
| Total non-current trade and other receivables | 16.4 | 17.5 |
Paragraphs:
20 Trade and Other Receivables
Trade receivables are non interest-bearing and are generally on 30–90 day payment terms depending on the geographical territory in which sales are generated. The carrying value of trade and other receivables also represents their fair value. During the year-ended 31 March 2019 a provision for impairment of $0.6M (2018: $0.6M) was recognised in operating expenses against receivables.
The net contract acquisition expense deferred within the Consolidated Statement of Profit or Loss was $0.9M of the total $259.9M of Sales and Marketing costs (2018: $8.4M / $239.9M).
Question:
What was recognised in operating expenses against receivables in 2019?
Answer: a provision for impairment of $0.6M (2018: $0.6M)